The Role of Heart Failure Pharmacotherapy After Left Ventricular Assist Device Support

Heart Failure Clinics

Volumn 10, Issue 4, 2014, Pages 653-660

  Rommel, John J ^a   O'Neill, Thomas J ^a   Lishmanov, Anton ^a   Katz, Jason N ^a   Chang, Patricia P ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Heart failure; Left ventricular assist device; Mechanical circulatory support; Medical therapy; Review

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CARVEDILOL; CLENBUTEROL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; HYDRALAZINE; ILOPROST; INOTROPIC AGENT; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; MILRINONE; NITRIC ACID DERIVATIVE; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; POTASSIUM; SILDENAFIL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

ASSISTED CIRCULATION; DIURETIC THERAPY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; EXERCISE; HEART FAILURE; HEART RIGHT VENTRICLE FAILURE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HUMAN; HYPERTENSION; LEFT VENTRICULAR ASSIST DEVICE; LONG TERM CARE; LONG TERM SURVIVAL; PACEMAKER IMPLANTATION; PERSISTENT PULMONARY HYPERTENSION; PRACTICE GUIDELINE; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME; COMPLICATION; HEART ASSIST DEVICE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; HYPERTENSION;

EID: 84908043144     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2014.07.008     Document Type: Review

References (43)

1. Kirklin J.K., Naftel D.C., Kormos R.L., et al. Third INTERMACS annual report: the evolution of destination therapy in the United States. JHeart Lung Transplant 2011, 30(2):115-123. 10.1016/j.healun.2010.12.001.
2. Ambardekar A.V., Buttrick P.M. Reverse remodeling with left ventricular assist devices: a review of clinical, cellular, and molecular effects. Circ Heart Fail 2011, 4(2):224-233. 10.1161/CIRCHEARTFAILURE.110.959684.
3. Jennings D.L., Jones M.C., Lanfear D.E. Assessment of the heart failure pharmacotherapy of patients with continuous flow left-ventricular assist devices. Int J Artif Organs 2012, 35(3):177-179. 10.5301/ijao.5000068.
4. Feldman D., Pamboukian S.V., Teuteberg J.J., et al. The 2013 international society for heart and lung transplantation guidelines for mechanical circulatory support: executive summary. JHeart Lung Transplant 2013, 32(2):157-187. 10.1016/j.healun.2012.09.013.
5. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. JAm Coll Cardiol 2013, 62(16):e147-e239. 10.1016/j.jacc.2013.05.019.
6. Klotz S., Danser A.H., Foronjy R.F., et al. The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. JAm Coll Cardiol 2007, 49(11):1166-1174.
7. Jugdutt B.I. Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. Curr Drug Targets Cardiovasc Haematol Disord 2003, 3(1):1-30.
8. Burkhoff D., Klotz S., Mancini D.M. LVAD-induced reverse remodeling: basic and clinical implications for myocardial recovery. JCard Fail 2006, 12(3):227-239.
9. Butler C.R., Jugdutt B.I. The paradox of left ventricular assist device unloading and myocardial recovery in end-stage dilated cardiomyopathy: implications for heart failure in the elderly. Heart Fail Rev 2012, 17(4-5):615-633. 10.1007/s10741-012-9300-8.
10. Klotz S., Foronjy R.F., Dickstein M.L., et al. Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. Circulation 2005, 112(3):364-374.
11. Klotz S., Burkhoff D., Garrelds I.M., et al. The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences?. Eur Heart J 2009, 30(7):805-812. 10.1093/eurheartj/ehp012.
12. Dandel M., Weng Y., Siniawski H., et al. Heart failure reversal by ventricular unloading in patients with chronic cardiomyopathy: criteria for weaning from ventricular assist devices. Eur Heart J 2011, 32(9):1148-1160. 10.1093/eurheartj/ehq353.
13. Matsumiya G., Monta O., Fukushima N., et al. Who would be a candidate for bridge to recovery during prolonged mechanical left ventricular support in idiopathic dilated cardiomyopathy?. JThorac Cardiovasc Surg 2005, 130(3):699-704.
14. Maybaum S., Mancini D., Xydas S., et al. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD working group. Circulation 2007, 115(19):2497-2505.
15. Sun B.C., Catanese K.A., Spanier T.B., et al. 100 long-term implantable left ventricular assist devices: the Columbia Presbyterian interim experience. Ann Thorac Surg 1999, 68(2):688-694.
16. Birks E.J., George R.S., Hedger M., et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation 2011, 123(4):381-390. 10.1161/CIRCULATIONAHA.109.933960.
17. Birks E.J., Tansley P.D., Hardy J., et al. Left ventricular assist device and drug therapy for the reversal of heart failure. NEngl J Med 2006, 355(18):1873-1884.
18. Refaat M., Chemaly E., Lebeche D., et al. Ventricular arrhythmias after left ventricular assist device implantation. Pacing Clin Electrophysiol 2008, 31(10):1246-1252. 10.1111/j.1540-8159.2008.01173.x.
19. Gheorghiade M., Adams K.F., Colucci W.S. Digoxin in the management of cardiovascular disorders. Circulation 2004, 109(24):2959-2964. 10.1161/01.CIR.0000132482.95686.87.
20. Georgiopoulou V.V., Kalogeropoulos A.P., Giamouzis G., et al. Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy. Circ Heart Fail 2009, 2(2):90-97. 10.1161/CIRCHEARTFAILURE.108.807032.
21. Rich S., Seidlitz M., Dodin E., et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998, 114(3):787-792.
22. Eshtehardi P., Mojadidi M., Khosraviani K., et al. Effect of digoxin on mortality in patients with isolated right ventricular dysfunction secondary to severe pulmonary hypertension. JAm Coll Cardiol 2014, 63(12S). 10.1016/S0735-1097(14)60750-6.
23. Lenneman A.J., Birks E.J. Treatment strategies for myocardial recovery in heart failure. Curr Treat Options Cardiovasc Med 2014, 16(3):287. 10.1007/s11936-013-0287-9.
24. McDiarmid A., Gordon B., Wrightson N., et al. Hemodynamic, echocardiographic, and exercise-related effects of the HeartWare left ventricular assist device in advanced heart failure. Congest Heart Fail 2013, 19(1):11-15. 10.1111/j.1751-7133.2012.00302.x.
25. Patlolla B., Beygui R., Haddad F. Right-ventricular failure following left ventricle assist device implantation. Curr Opin Cardiol 2013, 28(2):223-233. 10.1097/HCO.0b013e32835dd12c.
26. Palardy M., Nohria A., Rivero J., et al. Right ventricular dysfunction during intensive pharmacologic unloading persists after mechanical unloading. JCard Fail 2010, 16(3):218-224. 10.1016/j.cardfail.2009.11.002.
27. Mikus E., Stepanenko A., Krabatsch T., et al. Reversibility of fixed pulmonary hypertension in left ventricular assist device support recipients. Eur J Cardiothorac Surg 2011, 40(4):971-977. 10.1016/j.ejcts.2011.01.019.
28. Argenziano M., Choudhri A.F., Moazami N., et al. Randomized, double-blind trial of inhaled nitric oxide in LVAD recipients with pulmonary hypertension. Ann Thorac Surg 1998, 65(2):340-345.
29. Antoniou T., Prokakis C., Athanasopoulos G., et al. Inhaled nitric oxide plus iloprost in the setting of post-left assist device right heart dysfunction. Ann Thorac Surg 2012, 94(3):792-798. 10.1016/j.athoracsur.2012.04.046.
30. Lepore J.J., Maroo A., Bigatello L.M., et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 2005, 127(5):1647-1653. 10.1378/chest.127.5.1647.
31. Lewis G.D., Shah R., Shahzad K., et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007, 116(14):1555-1562.
32. Tedford R.J., Hemnes A.R., Russell S.D., et al. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail 2008, 1(4):213-219. 10.1161/CIRCHEARTFAILURE.108.796789.
33. Imamura T., Kinugawa K., Hatano M., et al. Bosentan improved persistent pulmonary hypertension in a case after implantation of a left ventricular assist device. JArtif Organs 2013, 16(1):101-104. 10.1007/s10047-012-0662-4.
34. LaRue S.J., Garcia-Cortes R., Ray S., et al. Treatment of secondary pulmonary hypertension with bosentan after left ventricular assist device implantation. JHeart Lung Transplant 2013, 32(4 Suppl):S110. 10.1016/j.healun.2013.01.228.
35. Maybaum S. Cardiac recovery during continuous-flow left ventricular assist device support: some good news from across the Atlantic. Circulation 2011, 123(4):355-357. 10.1161/CIRCULATIONAHA.110.005199.
36. Abstracts of the International Society for Heart and Lung Transplantation Thirty-First Annual Meeting and Scientific Sessions. April 13-16, 2011. San Diego, California, USA. JHeart Lung Transplant 2011, 30(4 Suppl):S8-S228.
37. Miller L.W., Pagani F.D., Russell S.D., et al. Use of a continuous-flow device in patients awaiting heart transplantation. NEngl J Med 2007, 357(9):885-896.
38. Pagani F.D., Miller L.W., Russell S.D., et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. JAm Coll Cardiol 2009, 54(4):312-321. 10.1016/j.jacc.2009.03.055.
39. Kihara S., Kawai A., Fukuda T., et al. Effects of milrinone for right ventricular failure after left ventricular assist device implantation. Heart Vessels 2002, 16(2):69-71.
40. Slaughter M.S., Pagani F.D., Rogers J.G., et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. JHeart Lung Transplant 2010, 29(4 Suppl):S1-S39. 10.1016/j.healun.2010.01.011.
41. Lampert B.C., Eckert C., Weaver S., et al. Blood pressure control in continuous flow left ventricular assist devices: efficacy and impact on adverse events. Ann Thorac Surg 2014, 97(1):139-146. 10.1016/j.athoracsur.2013.07.069.
42. John R., Kamdar F., Eckman P., et al. Lessons learned from experience with over 100 consecutive HeartMate II left ventricular assist devices. Ann Thorac Surg 2011, 92(5):1593-1599. [discussion: 1599-600]. 10.1016/j.athoracsur.2011.06.081.
43. Myers T.J., Bolmers M., Gregoric I.D., et al. Assessment of arterial blood pressure during support with an axial flow left ventricular assist device. JHeart Lung Transplant 2009, 28(5):423-427. 10.1016/j.healun.2009.01.013.